Embed Size (px)
Citation preview
Investor PresentationNASDAQ:BLFS
This presentation contains forward-looking statements, including, but not limited to, statements concerning the company’s anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Safe Harbor Statement
2
BIOPRESERVATION TOOLS FOR CELLS, TISSUES AND ORGANS
Preservation of Biologic Material
4
Allogeneic Transplant
DrugDiscovery
Biobanking
RegenerativeMedicine
Solid Organs
Tumor
Tissue Biopsies
Blood
Bone Marrow
Autologous Transplant
Biopreservation Challenges
Removed from the body - cells, tissues and organs enter a continuum of degradation – a race against time!
Survival - Quantity Viability - Quality Function
Ex Vivo Time
Via
bili
ty
Ex Vivo Time
Su
rviv
al
Ex Vivo Time
Fu
nct
ion
Hypothermia (cold chain management) is used to preserve biologic integrity and functional performance. Traditional methods and tools are not optimized and offer limited protection from preservation-induced stress, injury, and death.
5
Biopreservation Tools
6
Media and other tools designed to preserve biologics during ex vivo storage
Goal: maximize effectiveness of biologic based medicine
Shipping products designed to maintain stability of cells and tissues during transportation from patient to lab and back to patient
BIOPRESERVATION MEDIA
Patented technology; performance superior to commercial and homemade alternatives; also protected by trade secrets
Clinical grade preservation media made per GMP – facility and QMS certified to ISO13485
Our Biopreservation Media
Formulated to mitigate molecularcell stress during refrigeration and freeze/thaw process
Serum-free, protein-free, AOF; USP ingredients; US FDA Master Files
8
Preservedin traditional “home brew”
Human mesenchymal stem cells isolated from bone marrow; condition of cells after 5 days of cold storage, then returned to
culture conditions and assayed 24 hours later
Cell Yield Comparison
Preservedin BioLife
HypoThermosol®Cells are mostly dead
Cells are vital, thriving
9
Better Cell Yield = Cost Reductions
YieldYield
Cost Cost
LESSRequired to Achieve Desired Therapeutic
Effect
Source Material ManufacturedCell Products
LESSRequired
10
= MORE Doses
Limited Shelf Life = Cost Adder
If distribution range is limited by short shelf-life - multiple
production facilities requiredIncreased CAPEX requirements
Cell Factory
Cell Factory
Cell Factory
Cell Factory
Cell Factory
11
Our products extend shelf life to support worldwide distribution of cellular therapeutics
Reduced CAPEX requirements
Longer Shelf Life = Lower Costs
Cell Factory
12
biologistex™Intelligent, Informed, Precise
Biologic Materials Management
Cold Chain Biologistics
Patient
SourceMaterial
CellFactory
Manufactured Cell
Product
TemperatureControlled Container
TemperatureControlled Container
PreservationMedia
PreservationMedia
14
Current Biologistics Reality
All vaccines and 70% of
biologics are temperature
sensitive
Limited temp stability of traditional shipping
containers; cell viability
declines; lost and unusable
doses
Regenerative medicine therapies require precise thermal
protection during
shipment
Limited use of real-time
temperature monitoring
and reporting during
shipment
15
TIME
Economic Clinical
Biologistics Risks
Administering a thermally sensitive biologic dose that was exposed to unknown temperature excursions, packout errors or has exceeded it stability period
Cost of scrapping biologic source material or manufactured cell products
Clinical trial impact from poor biologistics management; lost dose, poor shipping container performance, temperature excursions
16
Rx $
Breakthrough Disruptive Technology
evo™ Smart Shipper
Simple, reusable, super insulating shipping container
Smart box – integrated cellular modem and payload monitoring
electronics
Cloud-hosted biologistics management app
Easy packout process
17
Current Solutions Inadequate
• Limited performance
• Technology essentially unchanged for over 25 years
• Single use
• Environmental impact
Foam Coolers Vacuum Panel Shipper
• Very large footprint; heavy
• Expensive to ship
• Complicated assembly
• Refrigerants must be preconditioned to multiple temperature ranges before use
18
Biologistex CCMSM
19
Cloud App Actionable Alerts
EVO # 31099282738 Alert: Delivered to St. Luke’s Medical Center on 5/5/2015 at 20:08 PST
LIMS/API
Web App – SaaS Business Model
Biologistex CCMSM
Real-time Location
Multiparameter Monitoring Configurable Alerts
20
EVO # 31099282738 Alert: Package is within 5 miles of destination as of 5/5/2015 at 21:19PST
SaaS Business Model
Potential to build a base of thousands of shippers deployed throughout the world – each generating subscription revenue for rental use and data access
21
OTHER SERVICES
Contract Manufacturing Services
Utilizing excessproduction capacity
Niche provider of aseptic media formulation, fill, and
finish services
23
Highly selective opportunities with strong alignment with our
capabilities
OUR MARKETS
3 Strategic Markets
BIOBANKING DRUG DISCOVERY REGENERATIVEMEDICINE
Umbilical cord blood banks
Adult stem cell banks
Tissue banks
Biorepositories
Hair transplant physicians
Pharmaceutical companies
Cell suppliers
Toxicity testing labs
Commercial cell therapy and tissue engineering companies
Hospital-based stem cell transplant centers
University-based clinical research labs
25
Products Used in 185 Clinical Trials
Pre-Clinical Phase I Phase II Phase III
Solid Tumors 4 17 536
Hematologic Malignancies 8 8 211
Heart Disease 1 2 28
Stroke 0 0 04
Joint Disease 4 1 21
Vision Loss 1 1 00
Immune Disorders 8 9 29
All Others 14 9 88
40 47 2177Each successful trial =
$0.5-2M/yearin revenue
26
Source: IMS Health, Evaluate Pharma
Biologistics Addressable Market
$4.9 Bil-lion
$2.6 Bil-lion
Specialized Packaging
Transportation
$500 Million Estimated Addressable Market for Shipping Containers
$3.2Billion
$5.1Billion
2004 2019
Source: iMarc Group, December 2013
27
Growing Demand for Biopreservation Media
Source: Biopreservation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 (Transparency Market Research, April, 2014)
Majorgrowth
expected from Regenerative
Medicine segment
$345Million
$820Million
2004 2019
28
INVESTMENT OPPORTUNITY
Complementary tools extend shelf life and increase survivalof cells and tissues
25% annualcore products revenue growth
$8.5M cashand no debtat end of Q1
NASDAQ: BLFS
30
IP embedded in more than 185 clinical trials
Significant Long-Term Growth Drivers
Biopreservation unmet needs
Increased regulatory scrutiny
Increased commercial
risk; trial failure
Smart, high performance containers
The Internet of Things; SaaS
Model
Regen Med Franchise
Revenue and Profit Growth; Enterprise Value
Building the Pipeline Capturing Value
31
$
500+existing customers
>185Regenerative medicine clinical projects and trials using BioLife products
Products used in rapid growth biobanking and drug discovery markets
$100MCurrent production revenue capacity
New SaaS offering will revolutionize biologistics management
Significant Growth
Potential
32
Investment FundamentalsMarch 31, 2015
Cash and Investments $8.6M
Total Debt $0.00
Total Stockholder Equity $12.7M
Shares Outstanding3/25/14 – issued 3.6M shares at $4.30
12M
Optionsmost in the money
1.4M
Warrants most at $4.75 – debt conversion/equity raise
7.4M
Average Volume ~100,000 shares
Market Cap ~$25M
Public Float 52%
33
BioLife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310Bothell, WA 98021
For additional questions or comments, please contact:
Michael Rice | President and [email protected] | (425) 686-6003
Daphne Taylor | CFO, VP - Finance & [email protected] | (425) 686-6002
NASDAQ:BLFS
34
